Menu
ReFocus on therapy unique to tumors with FGFR2 alterations
We are looking for a new way to help people with cancer—such as cholangiocarcinoma, breast, pancreatic, gastric, and others—who have an FGFR2 alteration (a genetic difference that can lead to cancer).
Learn about a possible therapy (RLY-4008) designed for people with a unique alteration in the FGFR2 gene.
See if you may qualify
Look at some of the inclusion criteria to see if you may qualify for the ReFocus study.
Contact a study clinic near you
Use the interactive map and search bar navigation to locate and contact a nearby study clinic location.
